Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

Oncotarget. 2022 Nov 17:13:1245. doi: 10.18632/oncotarget.28312.
No abstract available

Publication types

  • Published Erratum